| abstract |
HAPOI67 polypeptides and polynucleotides and methods for producing suchnpolypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizingnHAPOI67 polypeptides and polynucleotides in the design of protocols for the treatment ofninfections such as bacterial, fungal, protozoan and viral infections, particularly infections caused bynHIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure;nhypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction;nulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders,nincluding anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardationnand dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others andndiagnostic assays for such conditions. |